LabCorp's revenues jump after Covance buyout; Regen taps Charles River for preclinical project;

> In its first quarter after acquiring CRO giant Covance, LabCorp's ($LH) revenue jumped 23.9% to $1.4 billion. Covance's revenue decreased 1.9% to $624.6 million compared with the same period last year. Results

> Regen BioPharma has tapped Charles River Laboratories ($CRL) to run a preclinical study on its cell therapy designed to repair bone marrow. News

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.